{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:56:06Z","timestamp":1781862966043,"version":"3.54.5"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis (AAV) is known to cause rapidly progressive renal dysfunction, as well as high mortality, especially in older patients. In Japan, a high prevalence of microscopic polyangiitis (MPA) with myeloperoxidase (MPO)-ANCA among older patients has been reported; however, standard immunosuppressive therapy does not always lead to improved outcomes in this population. Here we report the case of a 93-year-old woman who developed rapidly progressive glomerulonephritis (RPGN) due to MPA and successfully returned home after multidisciplinary treatment. She was transferred from another hospital because of antibiotic-refractory fever. Serological testing revealed MPO-ANCA positivity and a renal biopsy demonstrated crescentic glomerulonephritis. She was diagnosed with RPGN due to MPA and was initiated on standard glucocorticoid therapy, despite her advanced age. Because of severe disease activity complicated by diffuse alveolar hemorrhage, noninvasive positive pressure ventilation, rituximab, avacopan, and plasma exchange combined with hemodialysis were introduced. This multidisciplinary approach successfully induced remission of her AAV with partial recovery of renal function. After rehabilitation for mobilization, the patient was discharged home. She currently attends outpatient follow-up independently without assistance. Although very elderly patients are often excluded from clinical trials, resulting in limited evidence regarding the efficacy and safety of therapeutic agents, appropriately dose-adjusted multidisciplinary treatment based on overall clinical conditions may improve outcomes, even in this population.<\/jats:p>","DOI":"10.3389\/fneph.2026.1803876","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:38:05Z","timestamp":1777354685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful reintegration of a very elderly patient with rapidly progressive glomerulonephritis due to microscopic polyangiitis after multidisciplinary treatment: a case report"],"prefix":"10.3389","volume":"6","author":[{"given":"Tatsuo","family":"Tsukamoto","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]},{"name":"Center for Preventive Medicine, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ohue","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]},{"name":"Center for Preventive Medicine, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-025-02643-6","article-title":"Temporal changes of the life and renal prognoses of patients with rapidly progressive glomerulonephritis in Japan, 1989-2019","volume":"29","author":"Nakajima","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road081","article-title":"Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update - secondary publication","volume":"34","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn354","article-title":"Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype","volume":"23","author":"Watts","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-013-0869-6","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-025-01210-8","article-title":"Aging in granulomatosis with polyangiitis and microscopic polyangiitis: from pathophysiology to clinical management","volume":"42","author":"Chevet","year":"2025","journal-title":"Drugs Aging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1656-1","article-title":"Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study","volume":"23","author":"Yamagata","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.11.029","article-title":"The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial","volume":"107","author":"Odler","year":"2025","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf122","article-title":"Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial","volume":"64","author":"Geetha","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/nejmoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20925","article-title":"Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Thietart","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket489","article-title":"Induction treatment of ANCA-associated vasculitis with a single dose of rituximab","volume":"53","author":"Turner-Stokes","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202308-1426oc","article-title":"Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-020-02341-6","article-title":"Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies","volume":"22","author":"Sada","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab Rev"}],"updated-by":[{"DOI":"10.3389\/fneph.2026.1895403","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1803876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:29:34Z","timestamp":1781861374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1803876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":25,"alternative-id":["10.3389\/fneph.2026.1803876"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1803876","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1803876"}}